Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 |
| SG&A Expenses | $3 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $3 | $0 | $1 |
| Operating Income | -$3 | -$0 | -$1 |
| % Margin | – | – | – |
| Other Income/Exp. Net | -$9 | $0 | $0 |
| Pre-Tax Income | -$13 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$13 | -$0 | -$1 |
| % Margin | – | – | – |
| EPS | -0.26 | -0.008 | -0.013 |
| % Growth | -3,233.3% | 40% | – |
| EPS Diluted | -0.26 | -0.008 | -0.013 |
| Weighted Avg Shares Out | 48 | 46 | 46 |
| Weighted Avg Shares Out Dil | 48 | 46 | 46 |
| Supplemental Information | – | – | – |
| Interest Income | $1 | $6 | $4 |
| Interest Expense | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$12 | -$0 | -$1 |
| % Margin | – | – | – |